VARON Highlights Respiratory Care for Older Adults

VARON México is drawing attention to respiratory health risks faced by older adults during the holiday season, emphasizing oxygen therapy solutions as support tools for people living with chronic respiratory conditions such as chronic obstructive pulmonary disease and asthma.

“In VARON, we are committed to helping older adults remain active and independent,” says the company in a press release, as it encourages families to prioritize respiratory health during winter months through the use of oxygen concentrators and portable devices.

Holiday gatherings often involve travel, extended social activity, and exposure to colder temperatures, all of which can pose challenges for older adults with respiratory conditions, reads the press release. While medical treatment remains central to managing diseases such as COPD and asthma, maintaining stable oxygen levels plays a key role in daily comfort, mobility, and overall quality of life. Insufficient oxygenation in older adults is commonly associated with fatigue, reduced physical capacity, and a higher likelihood of hospital admissions, particularly during winter.

Respiratory conditions continue to represent a significant health burden globally. Asthma alone affects over 300 million people worldwide, according to health data cited by Infomed, and allergic diseases impact a large share of the population. Despite advances in treatment and updated clinical guidelines, many patients struggle to maintain disease control, highlighting the importance of complementary approaches that support respiratory function in daily life.

Against this backdrop, VARON México is positioning oxygen concentrators and portable oxygen generators as practical tools that support independence and continuity of care for older adults during the holiday season. The company says these devices allow users to remain active at home and outside without interrupting prescribed oxygen therapy, offering reassurance to both patients and caregivers.

For home use, VARON promotes its Serene 5 Oxygen Concentrator, which delivers medical-grade oxygen at a concentration of 93±3% with adjustable flow rates from 0.5L to 5L per minute. The device supports both oxygen therapy and nebulization, operates quietly, and includes a large LCD display and integrated wheels to facilitate mobility within the home. These features are intended to simplify operation and reduce barriers to consistent use for older adults.

For users who require mobility beyond the home, the company highlights the VP-1 Portable Oxygen Concentrator. Weighing 2.75kg, the device provides adjustable pulse flow settings from levels one to five and is designed to support travel, errands, and outdoor activities. An LCD interface is intended to make the device accessible for both patients and caregivers, allowing oxygen therapy to continue during daily routines.

The emphasis on respiratory support during the holidays coincides with broader developments in respiratory medicine. In parallel, biotechnology company Generate:Biomedicines has announced plans to launch two Phase 3 clinical trials evaluating GB-0895, an AI-engineered monoclonal antibody for patients with severe asthma who remain uncontrolled on current treatments. The trials, known as SOLAIRIA-1 and SOLAIRIA-2, will enroll about 1,600 participants across more than 40 countries, including Mexico.

GB-0895 targets thymic stromal lymphopoietin, a cytokine involved in airway inflammation, and has been designed using machine-learning platforms to optimize affinity, specificity and half-life. Early-stage studies presented at the European Respiratory Society Congress reported sustained biomarker reductions and a half-life of approximately 89 days, supporting a twice-yearly dosing regimen. The antibody is also being evaluated in a Phase 1 study for COPD.

Experts note that while innovative therapies may expand treatment options in the future, day-to-day respiratory management remains critical. Laurie Lee, Chief Medical Officer for Immunology and Inflammation, Generate:Biomedicines, says the Phase 3 trials reflect an ongoing need for new approaches for patients who struggle with existing therapies. At the same time, healthcare systems continue to rely on a combination of pharmacological treatments, immunotherapy, and environmental management to reduce symptoms and prevent exacerbations.

As research increasingly integrates AI to improve diagnosis, risk prediction, and treatment adherence, companies are focusing on practical solutions that address immediate patient needs.